- Home
- NIPG vs MNPR Comparison
NIPG vs MNPR Comparison
Compare NIPG & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIPG
- MNPR
- Stock Information
- Founded
- NIPG 2014
- MNPR 2014
- Country
- NIPG Sweden
- MNPR United States
- Employees
- NIPG N/A
- MNPR N/A
- Industry
- NIPG
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- NIPG
- MNPR Health Care
- Exchange
- NIPG NYSE
- MNPR Nasdaq
- Market Cap
- NIPG 212.9M
- MNPR 250.0M
- IPO Year
- NIPG 2024
- MNPR 2019
- Fundamental
- Price
- NIPG $2.73
- MNPR $40.25
- Analyst Decision
- NIPG Strong Buy
- MNPR Strong Buy
- Analyst Count
- NIPG 1
- MNPR 4
- Target Price
- NIPG $12.00
- MNPR $43.00
- AVG Volume (30 Days)
- NIPG 166.3K
- MNPR 71.2K
- Earning Date
- NIPG 03-04-2025
- MNPR 03-27-2025
- Dividend Yield
- NIPG N/A
- MNPR N/A
- EPS Growth
- NIPG N/A
- MNPR N/A
- EPS
- NIPG N/A
- MNPR N/A
- Revenue
- NIPG $84,449,477.00
- MNPR N/A
- Revenue This Year
- NIPG $7.65
- MNPR N/A
- Revenue Next Year
- NIPG $14.38
- MNPR N/A
- P/E Ratio
- NIPG N/A
- MNPR N/A
- Revenue Growth
- NIPG 6.07
- MNPR N/A
- 52 Week Low
- NIPG $2.69
- MNPR $1.72
- 52 Week High
- NIPG $17.76
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- NIPG N/A
- MNPR 49.34
- Support Level
- NIPG N/A
- MNPR $38.80
- Resistance Level
- NIPG N/A
- MNPR $45.60
- Average True Range (ATR)
- NIPG 0.00
- MNPR 5.19
- MACD
- NIPG 0.00
- MNPR -1.50
- Stochastic Oscillator
- NIPG 0.00
- MNPR 9.37
About NIPG NIP GROUP INC SPON ADS EACH REPR 2 CL A ORD SHS
NIP Group Inc is a esports organization with operations across Asia, Europe and South America. It operate two esports brands: Ninjas in Pyjamas and eStar Gaming. Ninjas in Pyjamas, is a PC or console esports brand. eStar Gaming, is a mobile esports brand. The company has two reportable segments, including PRC and other entities, and Ninjas in Pyjamas. Key revenue is generated from PRC and other entities.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.